Share on LinkedInShare on LinkedIn

ARTICLE · 08 MAY 2018

Federal Circuit Affirms District Court Decision Finding Unclean Hands

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In Gilead Sciences, Inc. v. Merck & Co., the Federal Circuit affirmed the district court's decision finding that Merck's pre-litigation business ...

United StatesIntellectual Property

In Gilead Sciences, Inc. v. Merck & Co., the Federal Circuit affirmed the district court's decision finding that Merck's pre-litigation business misconduct and litigation misconduct barred it from asserting two patents against Gilead under the unclean hands doctrine. The district court decision vacated a $200 million jury award for infringement of Merck's patents.

The district court found that Dr. Durette, an inventor and patent agent for Merck, had participated in a conference call with Gildead's predecessor-in-interest related to the sofosbuvir compound.  In violation of a confidentiality agreement, Dr. Durette then used information from that call to narrow the claims of a pending application to target a specific group of compounds, including sofosbuvir.  Ultimately this application resulted in two patents, and Merck sued Gilead for infringement.  Although Dr. Durette repeatedly testified at his deposition that he could not recall whether he had participated in the

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from